# Joenja® (leniolisib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/leniolisib

> The PDUFA target action date for Joenja® (leniolisib), sponsored by Pharming Group N.V. (PHAR), is January 30, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the Joenja® (leniolisib) PDUFA date?

The PDUFA target action date for Joenja® (leniolisib), sponsored by Pharming Group N.V. (PHAR), is January 30, 2027. Status: scheduled. SEC Form 8-K: "On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027." Last confirmed October 27, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/leniolisib)

Source: SEC Form 8-K, accession 0001828316-26-000049, https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm (retrieved 2026-11-12). Last confirmed 2026-10-27. Cite: https://sec-api.dev/pdufa/leniolisib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Joenja® (leniolisib) |
| Codes |  |
| Sponsor | Pharming Group N.V. (PHAR) https://sec-api.dev/companies/phar/catalysts |
| Indications | apds in adult and pediatric patients 12 years of age and older in march 2023, children aged 4 to 11 years with apds, [children aged 4 to 11 years diagnosed with apds](https://sec-api.dev/indications/children-aged-4-to-11-years-diagnosed-with-apds), genetically defined primary immunodeficiencies, apds in adult and pediatric patients 4 years of age and older, and pediatric patients 12 years of age and older with apds, To treat activated phosphoinositide 3-kinase delta syndrome, [APDS](https://sec-api.dev/indications/apds) |
| Modality | small_molecule |
| FDA designations | fast track, orphan, priority review |

## Timeline

### Mar 2023: label expansion decision

- Status: completed, approved. Date confidence: month.
- First seen 2026-09-25, last confirmed 2026-09-25.
- SEC Form 8-K (accession 0001828316-26-000041): "The FDA approved Joenja for adults and pediatric patients aged 12 years and older with APDS in March 2023 and expanded the approval in September 2026 to include children aged 4 to 11 years weighing at least 27 kg." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm

### March 24, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat activated phosphoinositide 3-kinase delta syndrome.
- First seen 2024-12-11, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Joenja | leniolisib | 3/24/2023 | To treat activated phosphoinositide 3-kinase delta syndromeDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA217759 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230324, review_priority PRIORITY; sponsor_name PHARMING; product JOENJA (LENIOLISIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217759%22
- SEC Form 8-K (accession 0001828316-26-000037): "Joenja received approval from the U.S. FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000037/fdaapprovespharmingsjoenja.htm
- SEC Form 8-K (accession 0001828316-26-000031): "Joenja received approval from the FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm
- SEC Form 8-K (accession 0001828316-26-000004): "Joenja received approval from the FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000004/pharminggroupreceivescompl.htm
- SEC Form 8-K (accession 0001828316-25-000043): "Leniolisib, marketed under the brand name Joenja® in the U.S., received approval from the U.S. FDA for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000043/pharminggroupannouncesusfd.htm
- SEC Form 8-K (accession 0001828316-24-000037): "Leniolisib, marketed under the brand name Joenja® in the U.S., received approval from the U.S. Food and Drug Administration (FDA) for the treatment of APDS in adult and pediatric patients 12 years of age and older in March 2023." https://www.sec.gov/Archives/edgar/data/1828316/000182831624000037/pharmingannouncespositivet.htm
- SEC Form 10-K (accession 0001828316-25-000017): "On March 24, 2023, the FDA approved our New Drug Application, or NDA, of Joenja® (leniolisib) for the treatment of adult and pediatric patients 12 years of age and older with APDS." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000017/pharm-20241231.htm

### October 29, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-03-13, last confirmed 2025-05-08.
- SEC Form 8-K (accession 0001828316-25-000012): "The first patient was dosed in the study on October 29, 2024 and enrollment is progressing." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm
- SEC Form 8-K (accession 0001828316-25-000027): "We started a Phase II clinical trial evaluating leniolisib for PIDs with immune dysregulation linked to altered PI3Kẟ signaling in October 2024, and a Phase II clinical trial for CVID with immune dysregulation in February 2025." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000027/a2025q1pressrelease.htm
- SEC Form 8-K (accession 0001828316-25-000012): "We started the Phase II clinical trial evaluating leniolisib for PIDs with immune dysregulation linked to altered PI3Kẟ signaling in October 2024, and started a Phase II clinical trial for CVID with immune dysregulation in February 2025." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm

### December 11, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2025-03-13, last confirmed 2025-04-03.
- SEC Form 8-K (accession 0001828316-25-000012): "On December 11, 2024, we announced positive top line results for the multinational Phase III clinical trial for children 4 to 11 years of age, which has been evaluating leniolisib tablets in 21 children with APDS." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm
- SEC Form 10-K (accession 0001828316-25-000017): "On December 11, 2024, we announced positive top line results for the multinational Phase III clinical trial." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000017/pharm-20241231.htm

### Mar 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-04-02, last confirmed 2026-04-02.
- SEC Form 10-K (accession 0001828316-26-000015): "In March 2025, we submitted an NDA for patients aged 12 years and older to the Ministry of Food and Drug Safety." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/pharm-20251231.htm

### Mar 2025: FDA advisory committee meeting

- Status: scheduled. Date confidence: month. Indication: APDS in adult and adolescent patients 12 years of age and older.
- First seen 2025-03-13, last confirmed 2025-04-03.
- SEC Form 10-K (accession 0001828316-25-000017): "We received positive feedback from the Australian Advisory Committee on Medicines and in March 2025, we received approval for Joenja® (leniolisib) from the Australian TGA, for the treatment of APDS in adult and adolescent patients 12 years of age and older." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000017/pharm-20241231.htm
- SEC Form 8-K (accession 0001828316-25-000012): "In Australia, we filed a regulatory submission for patients 12 years of age and older in the third quarter of 2023 and, after positive feedback from the Australian Advisory Committee on Medicines, expect a final decision by mid-March 2025." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm

### March 20, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-03-20, last confirmed 2025-03-20.
- SEC Form 8-K (accession 0001828316-25-000014): "Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation" https://www.sec.gov/Archives/edgar/data/1828316/000182831625000014/pharminggroupannouncesfirs.htm
- SEC Form 8-K (accession 0001828316-25-000014): "Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000014/pharminggroupannouncesfirs.htm

### Jun 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: APDS in adult and pediatric patients 4 years of age and older.
- First seen 2025-07-31, last confirmed 2026-04-02.
- SEC Form 8-K (accession 0001828316-25-000034): "In June 2025, we submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the approval of leniolisib for the treatment of APDS in adult and pediatric patients 4 years of age and older." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000034/a2025hy1pressrelease.htm
- SEC Form 10-K (accession 0001828316-26-000015): "In July 2025, we submitted an sNDA to the FDA seeking approval of Joenja® (leniolisib) for children aged 4 to 11 years of age." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/pharm-20251231.htm

### Q3 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Indication: children aged 4 to 11 years diagnosed with APDS.
- First seen 2025-07-31, last confirmed 2025-07-31.
- SEC Form 8-K (accession 0001828316-25-000034): "We remain on track to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000034/a2025hy1pressrelease.htm

### July 31, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: children aged 4 to 11 years diagnosed with APDS.
- First seen 2025-11-06, last confirmed 2025-11-06.
- SEC Form 8-K (accession 0001828316-25-000049): "On July 31, 2025, we submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm

### October 1, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-10-01, last confirmed 2025-11-06.
- SEC Form 8-K (accession 0001828316-25-000049): "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm
- SEC Form 8-K (accession 0001828316-25-000043): "Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000043/pharminggroupannouncesusfd.htm

### January 31, 2026: PDUFA date

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2025-11-06, last confirmed 2025-11-06.
- SEC Form 8-K (accession 0001828316-25-000049): "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm
- SEC Form 8-K (accession 0001828316-26-000033): "Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm

### February 1, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-02-02, last confirmed 2026-07-30.
- SEC Form 8-K (accession 0001828316-26-000033): "Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm
- SEC Form 8-K (accession 0001828316-26-000004): "Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000004/pharminggroupreceivescompl.htm

### June 4, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: children aged 4 to 11 years with APDS.
- First seen 2026-06-04, last confirmed 2026-07-30.
- SEC Form 8-K (accession 0001828316-26-000031): "Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS" https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm
- SEC Form 8-K (accession 0001828316-26-000033): "On June 4, 2026, we announced that the U.S. Food and Drug Administration (FDA) had accepted our resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja as a treatment for children aged 4 to 11 years with APDS." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm
- SEC Form 8-K (accession 0001828316-26-000031): "Leiden, the Netherlands, June 4, 2026: Pharming Group (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm

### June 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Primary Immunodeficiency Disorders (PIDs).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06549114 (Leniolisib for Immune Dysregulation in PIDs): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT06549114

### July 30, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2026-10-27, last confirmed 2026-10-27.
- SEC Form 8-K (accession 0001828316-26-000049): "On July 30, 2026, we submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to 11 years who weigh 13 kg to 27 kg." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm

### August 12, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Common Variable Immunodeficiency (CVID).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06897358 (Leniolisib for Immune Dysregulation in CVID): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT06897358

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Common Variable Immunodeficiency (CVID).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06897358 (Leniolisib for Immune Dysregulation in CVID): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT06897358

### September 11, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-09-11, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217759 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260911, review_priority PRIORITY; sponsor_name PHARMING; product JOENJA (LENIOLISIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217759%22
- SEC Form 8-K (accession 0001828316-26-000049): "On September 11, 2026, we announced that the U.S. Food and Drug Administration (FDA) had approved our supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja as a treatment for children aged 4 to 11 years weighing at least 27 kg with APDS." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm
- SEC Form 8-K (accession 0001828316-26-000037): "Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000037/fdaapprovespharmingsjoenja.htm

### September 22, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: genetically defined primary immunodeficiencies.
- First seen 2026-04-02, last confirmed 2026-10-22.
- SEC Form 8-K (accession 0001828316-26-000039): "Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been accepted at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID), which will take place October 14-17, in the Netherlands." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000039/pharmingannouncespositivep.htm
- SEC Form 8-K (accession 0001828316-26-000047): "At ESID 2026, Pharming presented positive Phase II data for leniolisib in patients with genetically defined primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kδ signaling; Pharming expects topline Phase II results from its separate trial in CVID patients with immune dysregulation, with or without an identified genetic cause, in November 2026." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000047/q3announcementpr.htm
- SEC Form 8-K (accession 0001828316-26-000039): "•Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026" https://www.sec.gov/Archives/edgar/data/1828316/000182831626000039/pharmingannouncespositivep.htm
- SEC Form 10-K (accession 0001828316-26-000015): "We advanced two Phase II proof-of-concept clinical trials evaluating leniolisib in genetically defined PIDs linked to PI3K signaling and in CVID with immune dysregulation, with both studies on track for top-line data readouts in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/pharm-20251231.htm

### September 25, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-09-25, last confirmed 2026-10-27.
- SEC Form 8-K (accession 0001828316-26-000049): "On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm
- SEC Form 8-K (accession 0001828316-26-000041): "Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm

### October 14, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2026-10-14, last confirmed 2026-10-27.
- SEC Form 8-K (accession 0001828316-26-000049): "On October 14, 2026, we presented positive topline data from our Phase II trial of leniolisib in genetically identifiable PIDs with immune dysregulation at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID)." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm
- SEC Form 8-K (accession 0001828316-26-000045): "Leiden, the Netherlands, October 14, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today presented positive topline data from its Phase II trial of leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to altered PI3Kδ signaling." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000045/pharmingpresentspositiveph.htm

### October 24, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-07-30, last confirmed 2026-07-30.
- SEC Form 8-K (accession 0001828316-26-000033): "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm
- openFDA Drugs@FDA: "NDA217759 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260911, review_priority PRIORITY; sponsor_name PHARMING; product JOENJA (LENIOLISIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217759%22

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: APDS.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT05438407

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: APDS.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT05438407

### January 30, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-10-27, last confirmed 2026-10-27.
- SEC Form 8-K (accession 0001828316-26-000049): "On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027." https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: APDS.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05693129 (Pediatric Patients Aged 1 to 6 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-09 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT05693129

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: APDS.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05693129 (Pediatric Patients Aged 1 to 6 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-09 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT05693129

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: PIDs Linked to PI3K.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06990529 (Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-12 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT06990529

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: PIDs Linked to PI3K.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06990529 (Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-12 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." https://clinicaltrials.gov/study/NCT06990529

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [January 2027](https://sec-api.dev/fda-calendar/2027-01), [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/leniolisib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Joenja® (leniolisib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/leniolisib

```bibtex
@misc{secapidev_pdufa_leniolisib_20261116,
  title        = {Joenja® (leniolisib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/leniolisib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_leniolisib_20261116","title":"Joenja® (leniolisib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/leniolisib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
